KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Receivables - Net: 2013-2025

Historic Receivables - Net for Xenon Pharmaceuticals (XENE) over the last 10 years, with Mar 2025 value amounting to $8.6 million.

  • Xenon Pharmaceuticals' Receivables - Net rose 938.30% to $8.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.6 million, marking a year-over-year increase of 938.30%. This contributed to the annual value of $1.5 million for FY2024, which is 68.08% up from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Receivables - Net stood at $8.6 million for Q1 2025, which was up 488.77% from $1.5 million recorded in Q4 2024.
  • Xenon Pharmaceuticals' Receivables - Net's 5-year high stood at $8.6 million during Q1 2025, with a 5-year trough of $805,000 in Q3 2023.
  • In the last 3 years, Xenon Pharmaceuticals' Receivables - Net had a median value of $938,000 in 2024 and averaged $2.1 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Receivables - Net plummeted by 67.57% in 2023, and later skyrocketed by 938.30% in 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Receivables - Net (Quarterly) stood at $2.8 million in 2021, then slumped by 64.34% to $986,000 in 2022, then declined by 11.36% to $874,000 in 2023, then spiked by 68.08% to $1.5 million in 2024, then soared by 938.30% to $8.6 million in 2025.
  • Its Receivables - Net stands at $8.6 million for Q1 2025, versus $1.5 million for Q4 2024 and $938,000 for Q3 2024.